Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment by Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Salih Tünbekici, Gülçin Çelebi, Burçak Karaca

Get full text

Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics by Fatma Pınar Açar, Caner Acar, Damla Gunenc, Çağlar Arisoy, Asli Ece Solmaz, Asli Gecgel, Haydar Çağatay Yüksel, Gökhan Şahin, Oguzcan Ozkan, Zeynep Sila Gokdere, Nilay Duman, Burçak Karaca

Get full text

Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study by Sercan Ön, Barış Köksal, Zafer Arık, Burcu Caner, Duygu Ercan Uzundal, Ozan Yazıcı, Burcu Arslan Benli, Eda Eylemer Mocan, Can Güngör, Zeynep Gülsüm Güç, Seval Akay, Merve Keskinkılıç, Hande Dik Avcı, Burçak Karaca Yayla, Burcu Çakar, Ulus Ali Şanlı

Get full text

Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treate... by Nuri Karadurmus, Mehmet Ali Nahit Sendur, Burcak Karaca, Omer Fatih Olmez, Ilhan Hacibekiroglu, Hasan Senol Coskun, Serkan Degirmencioglu, Yasemin Kemal, Saadettin Kilickap, Ahmet Taner Sumbul, Burc Aydin, Hande Turna, Muhammet Ali Kaplan, Nalan Babacan, Umut Demirci, Alper Ata, Dilek Erdem, Ahmet Ozet, Huseyin Abali

Get full text